Drug Profile
AB 201
Alternative Names: AB201-Arca Biopharma; NAPc2; Nematode Anticoagulant Protein c2; Recombinant NAPc2; Recombinant Nematode Anticoagulant c2; rNAPc2Latest Information Update: 06 Apr 2022
Price :
$50
*
At a glance
- Originator Dendreon Corporation
- Developer ARCA biopharma Inc
- Class Anti-inflammatories; Anticoagulants; Antivirals; Recombinant proteins
- Mechanism of Action Angiogenesis inhibitors; Tissue factor-factor VIIa complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Blood coagulation disorders; COVID 2019 infections
- Preclinical Marburg virus disease
- Discontinued Acute coronary syndromes; Colorectal cancer; Deep vein thrombosis; Disseminated intravascular coagulation; Ebola virus infections
Most Recent Events
- 31 Mar 2022 Efficacy and safety data from phase a phase IIb/III ASPEN-COVID-19 trial in COVID-2019 infections and Blood coagulation disorders released by ARCA biopharma
- 19 Jan 2022 ARCA biopharma completes its phase IIb/III ASPEN-COVID-19 trial in COVID-2019 infections (In adults, In the elderly) and Blood coagulation disorders (In adults, In the elderly) in USA, Argentina and Brazil (SC) (NCT04655586)
- 02 Dec 2021 ARCA biopharma completes enrollment in a phase IIb ASPEN-COVID-19 trial in COVID-2019 infections in USA, Argentina and Brazil